Dual drug therapy delayed treatment resistance in melanoma

Two drugs being evaluated by the FDA slowed the development of treatment resistance in persons with metastatic malignant melanoma positive for the BRAF protein.

http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/http://www.oncologynurseadvisor.com/dual-drug-therapy-delayed-treatment-resistance-in-melanoma/article/264688/